CME Breakfast Symposium
A Conversation with the Experts: New Scientific, Genetic, and Clinical Insights into the Management of Triglycerides
Friday, October 23, 2015 | 6:30 - 8:00am
Supported by an educational grant from Amarin Pharma, Inc.

SYMPOSIUM OVERVIEW
Hypertriglyceridemia is a highly prevalent, yet modifiable, risk factor for pancreatitis, cardiovascular disease (CVD) and associated complications. Despite evidence linking elevated serum triglycerides to cardiovascular (CV) events, a wide gap separates national treatment recommendations and real world practices, leaving patients at risk for excess morbidity and mortality. With several pharmacologic therapies now available for severe hypertriglyceridemia, clinicians must be well informed regarding the safety, efficacy, and tolerability of these agents alone and in combination with statins. During this symposium, expert panelists will address the latest topics and answer key questions on triglyceride management through brief didactic presentations based on recent data and evidence, and engaging conversation in an informal roundtable setting.

LEARNING OBJECTIVES
Upon completion of these educational activities, participants will be better able to:

- Review the etiology and pathophysiology of hypertriglyceridemia as well as its impact on CVD risk.
- Describe the emerging genetic research establishing a causal pathway between TGs and coronary heart disease.
- Evaluate the lipid-altering effects and impact on CV risk of available therapeutic strategies for managing high TG and mixed dyslipidemia, including niacin, fibrates, prescription OM3FAs, and combination therapies such as OM3FAs and statins.
- Appraise the latest findings on the mechanisms by which OM3FAs affect atherogenesis.
- Enhance clinical decision-making when managing patients with elevated triglycerides and/or mixed dyslipidemia to optimize patient outcomes.

Note: Agenda & Faculty are subject to change.
Agenda & Faculty

Welcome and Introductions
Chairperson: Peter H. Jones, MD

A Conversation with the Experts: New Scientific, Genetic, and Clinical Insights into the Management of Triglycerides
Presenter: Peter H. Jones, MD

Plasma Triglycerides and Risk for Coronary Heart Disease: What Does Human Genetics Teach Us?
Presenter: Sekar Kathiresan, MD

The Pharmacologic Differences of TG-Lowering Agents and Their Differential Effects on Components of Atherogenesis
Presenter: R. Preston Mason, MBA, PhD

Selecting Appropriate Treatment Options for Patients with Hypertriglyceridemia
Presenter: Howard Weintraub, MD

Audience Question and Answer, Summary and Closing Remarks
Chairperson: Peter H. Jones, MD
Discussants: Sekar Kathiresan, MD; R. Preston Mason, MBA, PhD; Howard Weintraub, MD

Note: Agenda and Faculty subject to change.